Cassava Sciences Inc
SAVA2.305USD
+0.185+8.73%
Market hours （ET）Quotes delayed by 15 min
111.35MMarket Cap
LossP/E TTM
More Details of Cassava Sciences Inc Company
Cassava Sciences, Inc. is a clinical-stage biopharmaceutical company focused on neuroscience. The Company's science is based on stabilizing, but not removing, a critical protein in the Alzheimer’s brain. Its scientific approach for the treatment of Alzheimer's disease seeks to simultaneously suppress both neurodegeneration and neuroinflammation. It has two biopharmaceutical assets under development: Simufilam and SavaDx. Simufilam, its lead therapeutic product candidate, is an oral treatment for Alzheimer’s disease dementia. Simufilam targets an altered form of a protein called filamin A (FLNA) in the Alzheimer’s brain. It is conducting two randomized placebo-controlled Phase III clinical trials of oral simufilam in patients with Alzheimer’s disease dementia. SavaDx, its lead investigational diagnostic product candidate, is a way to detect the presence of Alzheimer’s disease from a small sample of blood. SavaDx is a research-use only, non-safety related exploratory biomarker.
Company Info
Ticker SymbolSAVA
Company nameCassava Sciences Inc
IPO dateJul 14, 2000
CEOMr. Richard J. (Rick) Barry
Number of employees30
Security typeOrdinary Share
Fiscal year-endJul 14
Address6801 N. Capital of Texas Highway
CityAUSTIN
Stock exchangeNASDAQ Capital Market Consolidated
CountryUnited States of America
Postal code78731
Phone15125012444
Websitehttps://www.cassavasciences.com/
Ticker SymbolSAVA
IPO dateJul 14, 2000
CEOMr. Richard J. (Rick) Barry
Company Executives
Name
Name/Position
Position
Shareholding
Change
Mr. Richard J. (Rick) Barry
Mr. Richard J. (Rick) Barry
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
469.56K
+33.33%
Mr. Eric J. Schoen
Mr. Eric J. Schoen
Chief Financial Officer
Chief Financial Officer
11.50K
-35.61%
Dr. Robert Z. Gussin, Ph.D.
Dr. Robert Z. Gussin, Ph.D.
Independent Director
Independent Director
10.62K
-16.66%
Mr. Michael J. O'Donnell, Esq.
Mr. Michael J. O'Donnell, Esq.
Independent Director
Independent Director
6.87K
-16.66%
Dr. Jack Moore, Ph.D.
Dr. Jack Moore, Ph.D.
Senior Vice President - Clinical Development
Senior Vice President - Clinical Development
--
--
Dr. Patrick J. Scannon, M.D., Ph.D.
Dr. Patrick J. Scannon, M.D., Ph.D.
Independent Director
Independent Director
--
--
Ms. Freda Nassif
Ms. Freda Nassif
Chief Business Officer
Chief Business Officer
--
--
Mr. Pierre Gravier
Mr. Pierre Gravier
Independent Director
Independent Director
--
--
Dr. Claude Nicaise, M.D.
Dr. Claude Nicaise, M.D.
Independent Chairman of the Board
Independent Chairman of the Board
--
--
Mr. Robert Anderson, Jr.
Mr. Robert Anderson, Jr.
Independent Director
Independent Director
--
--
View more
Name
Name/Position
Position
Shareholding
Change
Mr. Richard J. (Rick) Barry
Mr. Richard J. (Rick) Barry
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
469.56K
+33.33%
Mr. Eric J. Schoen
Mr. Eric J. Schoen
Chief Financial Officer
Chief Financial Officer
11.50K
-35.61%
Dr. Robert Z. Gussin, Ph.D.
Dr. Robert Z. Gussin, Ph.D.
Independent Director
Independent Director
10.62K
-16.66%
Mr. Michael J. O'Donnell, Esq.
Mr. Michael J. O'Donnell, Esq.
Independent Director
Independent Director
6.87K
-16.66%
Dr. Jack Moore, Ph.D.
Dr. Jack Moore, Ph.D.
Senior Vice President - Clinical Development
Senior Vice President - Clinical Development
--
--
Dr. Patrick J. Scannon, M.D., Ph.D.
Dr. Patrick J. Scannon, M.D., Ph.D.
Independent Director
Independent Director
--
--
Revenue Breakdown
No Data
No Data
By Business
By Region
No Data
Shareholding Stats
Updated: Sat, May 17
Updated: Sat, May 17
Shareholders
Shareholder Types
Shareholders
Shareholders
Proportion
BlackRock Institutional Trust Company, N.A.
6.78%
Nachtrab (Matthew)
4.69%
The Vanguard Group, Inc.
4.49%
Barbier (Remi)
4.28%
Two Sigma Investments, LP
2.81%
Other
76.95%
Shareholders
Shareholders
Proportion
BlackRock Institutional Trust Company, N.A.
6.78%
Nachtrab (Matthew)
4.69%
The Vanguard Group, Inc.
4.49%
Barbier (Remi)
4.28%
Two Sigma Investments, LP
2.81%
Other
76.95%
Shareholder Types
Shareholders
Proportion
Investment Advisor
16.43%
Individual Investor
12.79%
Investment Advisor/Hedge Fund
5.95%
Research Firm
4.58%
Hedge Fund
4.46%
Bank and Trust
0.58%
Pension Fund
0.30%
Venture Capital
0.11%
Other
54.80%
Institutional Shareholding
Updated: Tue, Jul 1
Updated: Tue, Jul 1
Reporting Period
No. of institutions
Shares Held
Proportion
Change
2025Q2
353
21.84M
45.21%
-1.76M
2025Q1
363
22.22M
46.00%
-1.56M
2024Q4
360
23.73M
49.12%
+4.41M
2024Q3
371
20.81M
43.35%
+1.72M
2024Q2
372
16.74M
35.19%
-1.63M
2024Q1
372
14.95M
34.46%
-4.56M
2023Q4
382
18.11M
42.87%
+1.40M
2023Q3
392
15.72M
37.42%
-103.08K
2023Q2
410
14.43M
34.53%
-1.76M
2023Q1
415
14.61M
34.97%
-1.98M
View more
Shareholder Activity
Name
Shares Held
Proportion
Change
Chg %
Date
BlackRock Institutional Trust Company, N.A.
3.27M
6.78%
-132.04K
-3.88%
Mar 31, 2025
Nachtrab (Matthew)
2.27M
4.69%
+2.27M
--
Aug 16, 2024
The Vanguard Group, Inc.
2.44M
5.06%
-60.35K
-2.41%
Mar 31, 2025
Barbier (Remi)
2.07M
4.28%
+727.36K
+54.36%
Sep 30, 2024
Two Sigma Investments, LP
1.36M
2.81%
+190.09K
+16.26%
Mar 31, 2025
Robertson (Sanford R)
1.34M
2.78%
-5.00K
-0.37%
May 16, 2024
Geode Capital Management, L.L.C.
1.03M
2.13%
+19.60K
+1.95%
Mar 31, 2025
State Street Global Advisors (US)
873.95K
1.81%
-122.72K
-12.31%
Mar 31, 2025
J.P. Morgan Securities LLC
749.56K
1.55%
+384.11K
+105.10%
Mar 31, 2025
Susquehanna International Group, LLP
552.02K
1.14%
+271.63K
+96.87%
Mar 31, 2025
View more
Related ETFs
Updated: Sat, Aug 2
Updated: Sat, Aug 2
Name
Proportion
iShares Neuroscience and Healthcare ETF
0.2%
Texas Capital Texas Small Cap Equity Index ETF
0.09%
iShares Micro-Cap ETF
0.02%
ProShares Hedge Replication ETF
0%
iShares ESG Aware MSCI USA Small-Cap ETF
0%
ALPS Medical Breakthroughs ETF
0%
iShares Morningstar Small-Cap ETF
0%
Virtus LifeSci Biotech Clinical Trials ETF
0%
JPMorgan BetaBuilders US Small Cap Equity ETF
0%
Texas Capital Texas Equity Index ETF
0%
View more
iShares Neuroscience and Healthcare ETF
Proportion0.2%
Texas Capital Texas Small Cap Equity Index ETF
Proportion0.09%
iShares Micro-Cap ETF
Proportion0.02%
ProShares Hedge Replication ETF
Proportion0%
iShares ESG Aware MSCI USA Small-Cap ETF
Proportion0%
ALPS Medical Breakthroughs ETF
Proportion0%
iShares Morningstar Small-Cap ETF
Proportion0%
Virtus LifeSci Biotech Clinical Trials ETF
Proportion0%
JPMorgan BetaBuilders US Small Cap Equity ETF
Proportion0%
Texas Capital Texas Equity Index ETF
Proportion0%
Dividend
A total of
0.00
USD has been distributed in dividends over the past 5 years.
Date
Dividend
Record Date
Payment Date
Ex-dividend Date
No Data
Stock Split
Date
Type
Ratio
No Data
Date
Type
Ratio
No Data
